Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1
Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1
复制标题
DOI：
10.1038/s41392-021-00649-6
复制
发表时间：
2021
影响因子：
39.3
通讯作者：
Yuanyu Huang
中科院分区：
文献类型：
--
作者：
Ge Yang;Ziyue Li;Mohammed Irfan;Liping Zhao;Wei Wei;Haihua Xiao;Weisheng Guo;Yongxiang Zhao;Feng Qu;Yuanyu Huang
The ongoing outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a great threat to the public health of people and the normal economic and social development around the world. As of January 8, 2021, more than 88 million people were infected with SARS-CoV-2, resulting in more than 1.9 million death. Early detection and treatment of SARS-CoV-2 are of prime significance for effective control of COVID-19. Currently, nucleic acid amplification (e.g., RT-PCR) and detection of IgG, IgM, or viral antigen are employed in clinical diagnosis, and there is only one drug, remdesivir, was approved for COVID-19 treatment. Although various virus-based and host-based therapeutics, such as remdesivir, lopinavir/ritonavir, umifenovir, ribavirin, chloroquine, hydroxychloroquine, interferon, Tocilizumab, convalescent plasma, neutralizing antibody, and traditional Chinese medicine, have been tested to treat COVID-19, developing novel therapeutic are urgently required. Nucleic acid modalities including aptamer oligonucleotide constitute a promising next-generation solution for disease diagnosis and treatment. Developing an aptamerbased theranostic regimen represents a potentially effective way to control COVID-19.
